ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LEXX vs SNGX // GROSS PROFIT MARGIN

Lexaria Bioscience Corp. (NASDAQ) VS. Soligenix Inc. (NASDAQ) • 15-METRIC TALLY: LEXX 1 — SNGX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LEXX VS. SNGX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LEXX SNGX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 52.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 LEXX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.6 49.5 -0.83 SNGX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $7.9M $8.0M -$96.4K SNGX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LEXX REV SNGX REV LEXX GROSS % SNGX GROSS % LEXX FCF SNGX FCF
FY 2025 $705.9K $0 98.0% — -$10.5M -$10.3M
FY 2024 $464.3K $119.4K 98.0% 0.0% -$5.0M -$8.4M
FY 2023 $226.2K $839.4K — — -$5.9M -$8.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LEXX // BETA —
SNGX // BETA —